Bando H, Yamashita T, Matunaga Y, Kinoshita S, Doi H, Ogushi F, Shimada H, Tsubura E, Morioka S, Ishimi H
Gan To Kagaku Ryoho. 1984 Apr;11(4):888-93.
Comparative studies of alternating non-cross resistant chemotherapy, A.V.N.-D.V.C. (ACNU + VCR + PCZ-ADM + VCR + CPA) was carried out on 19 patients with small cell lung cancer. A.V.N. (A. V.F.) therapy on 45 patients and D.V.C. therapy on 19 patients were used as historical control, respectively. A.V.N. (A.V.F.) therapy was composed of ACNU (2.5 mg/kg, day 1), VCR (0.02 mg/kg, once every week) and PCZ (1 mg/kg, daily) (or FT-207 (15 mg/kg, daily], and duration of one course was 6 to 8 weeks. D.V.C. therapy was composed of ADM (1 mg/kg, day 1) VCR (0.02 mg/kg, days 1 and 5) and CPA (2 mg/kg, days 1 to 5), and repeated every 4 weeks. A.V.N.-D.V.C. therapy was done by a timely alternation of one course of A.V.N. and two course of D.V.C. Reduction rate of tumor size was 84% in A.V.N.-D.V.C. therapy, 62% in A.V.N. (A.V.F.) therapy and 26% in D.V.C. therapy, respectively. Median survival time was 13 months on A.V.N.-D.N.C. therapy, 8.5 months and A.V.N. (A. V.F.) therapy and 4 months on D.V.C. therapy. Significant prolongation of median survival time was obtained in A.V.N.-D.V.C. therapy in comparison with that of historical controls. Major toxicity in A.V.N.-D.V.C. therapy was slight bone marrow suppression.
对19例小细胞肺癌患者进行了交替非交叉耐药化疗A.V.N.-D.V.C.（ACNU + VCR + PCZ - ADM + VCR + CPA）的对比研究。分别将45例接受A.V.N.（A.V.F.）治疗的患者和19例接受D.V.C.治疗的患者作为历史对照。A.V.N.（A.V.F.）治疗方案由ACNU（2.5mg/kg，第1天）、VCR（0.02mg/kg，每周1次）和PCZ（1mg/kg，每日）（或FT - 207（15mg/kg，每日）组成，一个疗程持续6至8周。D.V.C.治疗方案由ADM（1mg/kg，第1天）、VCR（0.02mg/kg，第1天和第5天）和CPA（2mg/kg，第1天至第5天）组成，每4周重复一次。A.V.N.-D.V.C.治疗是通过一个疗程的A.V.N.和两个疗程的D.V.C.适时交替进行。A.V.N.-D.V.C.治疗的肿瘤缩小率分别为84%，A.V.N.（A.V.F.）治疗为62%，D.V.C.治疗为26%。A.V.N.-D.N.C.治疗的中位生存时间为13个月，A.V.N.（A.V.F.）治疗为8.5个月，D.V.C.治疗为4个月。与历史对照相比，A.V.N.-D.V.C.治疗的中位生存时间显著延长。A.V.N.-D.V.C.治疗的主要毒性是轻度骨髓抑制。
